

HYBRID FORM

# BELGRADE Valve International Symposium

12 – 13.06.2021  
Hotel Hilton, Belgrade

UDRUŽENJE KARDIOLOGA SRBIJE  
CARDIOLOGY SOCIETY OF SERBIA



Udruženje kardioloških hirurga Srbije  
Serbian Society for Cardiovascular Surgery



## Respected Colleagues, Dear Friends,

It is a great pleasure and honor to cordially welcome you to the first Belgrade Valve International Symposium (BELVIS) which will be held on June 12 - June 13, 2021, at the Hilton Hotel. The meeting is being jointly organized by cardiologists and cardiac surgeons of Serbia, under the auspices of the Cardiology Society of Serbia, the Serbian Society for Cardiovascular Surgery, the Medical Faculty of the University of Belgrade, Society for Cardiovascular pathology of Serbian Academy of Sciences and Art and the Ministry of Health of the Republic of Serbia.

The idea of the meeting is to join cardiologists and cardiac surgeons in discussions related to valvular heart diseases, its risk stratification, imaging and treatment. The meeting is intended to be practical, interactive and to offer interesting scientific and educational content to cardiovascular subspecialists, but also to general physicians, fellows and all others who are interested in this topic. Belvis 2021 will be held with live transmissions from conference room with only lecturers and panelists present in the room. We do hope that BELVIS 2021 will meet your expectations and trust that you will enjoy visiting our beautiful and vivid city.



Marko Banović,  
cardiologist



Svetozar Putnik,  
cardiac surgeon

<b>08.30–10.00</b>	<b>Session: AORTIC VALVE DISEASE I</b> Moderators: R Binder, M Banovic, W Wojakowski Panel: R Binder, M Banovic, G Biondi-Zoccai, W Wojakowski, M Nedeljkovic, B Ivanovic, B Beleslin, A Mikic, Lj Jovovic, S Micovic
<b>08.30–08.45</b>	<b>Treatment of asymptomatic AS – a next frontier?</b> M Banovic, Belgrade (Serbia)
<b>08.50–09.05</b>	<b>Reconciling randomized trial and observational study evidence on new-generation TAVI devices</b> G Biondi-Zoccai, Rome (Italy)
<b>09.10–09.25</b>	<b>Transcatheter aortic valve-in-valve interventions</b> W Wojakowski, Katowice (Poland)
<b>09.30–09.45</b>	<b>TAVI and low coronary ostia: The BASILICA Procedure</b> R Binder, Wells (Austria)
<b>10.30–11.00</b>	<b>Medtronic Symposium</b> Moderator: S Putnik, H Gasparovic
<b>10.30–10.45</b>	<b>Future perspectives in LVAD therapy: insight from "Lateral" trial</b> S Putnik, Belgrade (Serbia)
<b>10.45–11.00</b>	<b>Challenges of LVAD implantation during Covid-19 pandemic</b> H Gasparovic, Zagreb (Croatia)
<b>11.30–13.30</b>	<b>Session: VALVE DISEASE @ HEART FAILURE</b> Moderators: M Penicka, H Gasparovic, A Redzek Panel: M Penicka, H Gasparovic, A Ristic, I Stojanovic, A Redzek, P Otasevic, I Nedeljkovic, M Dobric, M Zdravkovic, V Mitov
<b>11.30–11.45</b>	<b>Cardiac MRI: Advantages and defects in evaluating patients with valve disease and heart failure</b> M Penicka, Aalst (Belgium)
<b>11.50–12.05</b>	<b>Replacement or repair in heart failure patients with primary MR</b> I Stojanovic, Belgrade (Serbia)

<b>12.10–12.25</b>	<b>Treatment of persistent secondary pulmonary hypertension</b> A Ristic, Belgrade (Serbia)
<b>12.30–12.45</b>	<b>Heart failure with mid-range ejection fraction: the grey zone</b> P Otasevic, Belgrade (Serbia)
<b>12.50–13.05</b>	<b>cmRI after Covid-19 infection: what lies behind the horizon?</b> M Zdravkovic, Belgrade (Serbia)
<b>13.45–14.15</b>	<b>Abbott Symposium</b> Moderator: S Putnik
<b>13.45–14.00</b>	<b>Patient selection for LVAD implantation</b> E Nestorovic, Belgrade (Serbia)
<b>14.00–14.15</b>	<b>Heart failure registry</b> L Velicki, Novi Sad (Serbia)
<b>14.30–15.30</b>	<b>Astra Zeneca Symposium</b>
	<b>Forxiga in cardiologist focus</b>
<b>14.30–14.45</b>	<b>Presentation 1</b> S Salinger, Nis (Serbia)
<b>14.45–15.00</b>	<b>Presentation 2</b> L Velicki, Novi Sad (Serbia)
	<b>Brilique – from revascularization to prolonged use</b>
<b>15.00–15.15</b>	<b>Presentation 1</b> V Vukcevic, Belgrade (Serbia)
<b>15.15–15.30</b>	<b>Presentation 2</b> S Putnik, Belgrade (Serbia)
<b>16.00–17.30</b>	<b>Session: AORTIC VALVE DISEASE II</b> Moderators: B lung, M Deja, V Vukcevic Panel: B lung, V Vukcevic, R Rajani, S Stojkovic, M Deja, S Putnik, M Nedeljkovic, A Stojsic-Milosavljevic, T Kostic, M Banovic
<b>16.00–16.15</b>	<b>Changes in trends in valvular diseases in Europe in 2021</b> B lung, Paris (France)

- 16.20–16.35**     **Aortic stenosis and coronary artery disease – a two tale story**  
V Vukcevic, Belgrade (Serbia)
- 16.40–16.55**     **Tailoring antithrombotic therapy to the TAVI patient**  
S Stojkovic, Belgrade Serbia)
- 17.00–17.15**     **Sutureless SAVR: Challenges and advantages**  
S Putnik, Belgrade (Serbia)

**SUNDAY 13.06.2021**

access to session 

**08.00–09.00**     **AVATAR trial SC meeting**

**09.30–11.30**     **Session: MITRAL VALVE DISEASE**

Moderators: R Rajani, J Bartunek, G Milasinovic

Panel: R Rajani, B Lung, G Milasinovic, M Deja, J Bartunek, S Salizzoni, S Putnik, M Banovic, Z Perisic, I Bilbija, M Peric

**09.30–09.45**     **Imaging planning for complex structural mitral valve interventions?**

R Rajani, London (UK)

**09.50–10.05**     **The role of CRT in mitral regurgitation management**

G Milasinovic, Belgrade (Serbia)

**10.10–10.25**     **Percutaneous treatment of mitral valve disease**

J Bartunek, Aalst (Belgium)

**10.30–10.45**     **Transventricular beating heart mitral valve repair: state of the art and future implications**

S Salizzoni, Turin (Italy)

**10.50–11.05**     **Surgical treatment of functional MR – When and how**

M Deja, Katowice (Poland)

Thanks to our sponsors!

Platinum sponsor

**Medtronic**

Further, Together

 **Abbott**

**AstraZeneca** 

Sponsor

 **Hemofarm**  
STADA GRUPA

 **Galenika** Posvećeni ljudima,  
verni zdravlju

 **Actavis**

 **PATENT CO.**<sup>®</sup>

Zlatan Haskić